✦ LIBER ✦

Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease

✍ Scribed by von Vigier, Rodo O.; Zberg, Priska M.; Teuffel, Oliver; Bianchetti, Mario G.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness and safety of the angioten

✍ Lorenzo M.D. Franscini; Rodo O. Von Vigier; Roger Pfister; Carmen Casaulta-Aebis 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 171 KB

A Review of the Clinical Experience with

✍ Waeber, Bernard 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB

E9 Dose-related reductions in blood pres

✍ R.M. Guthrie; R. Saini; S. Hannah; E. Adler; I. Svensborn 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 94 KB

Hemodynamic Effects of the Angiotensin I

✍ Michael Schepke; Eva Werner; Erwin Biecker; Peter Schiedermaier; Jörg Heller; Ma 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 210 KB

Molecular and clinical response to angio

✍ Valeria R. Mas; Teresita Alvarellos; Daniel G. Maluf; Andrea Ferreira-Gonzalez; 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 740 KB

Enhanced Angiotensin II type 1 receptor

✍ Helena Chon; Jutta Neumann; Peter Boer; Jaap A. Joles; Branko Braam 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 291 KB